EGFR and lung cancer: Nonetheless, the effectiveness of dasatinib is poor in both lung cancer A549 cells with wild-type EGFR or in H1975 cells harbouring L858R and T790M mutations [28], which is similar to the medical outcome of gefitinib treatment.